Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss
Blood Podcast
00:00
Introduction
Exploring the efficacy of Brent Tuxemab in classical Hodgkin lymphoma and addressing resistance mechanisms in relapsed B-cell lymphomas, emphasizing the importance of personalized treatment strategies for older patients.
Transcript
Play full episode
